GlaxoSmithKline plc (GSK,GSK.L) said Tuesday that the U.S. Food and Drug Administration has approved Tanzeum subcutaneous injection as a once-weekly treatment for type 2 diabetes.
Tanzeum has been approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Tanzeum is a glucagon-like peptide-1 receptor agonist, a hormone that helps normalize blood sugar levels. The drug's safety and effectiveness were evaluated in eight clinical trials involving more than 2,000 patients with type 2 diabetes.
Tanzeum has a boxed warning to warn that tumors of the thyroid gland have been observed in rodent studies with some GLP-1 receptor agonists, but that it is unknown whether Tanzeum causes thyroid C-cell tumors, including a type of thyroid cancer called medullary thyroid carcinoma, in humans.
GlaxoSmithKline expects to launch Tanzeum in the U.S. in the third quarter of 2014.
GlaxoSmithKline shares closed Tuesday's regular trading session at $52.32, up 48 cents. The company's shares closed 0.26% higher at 1,547.00 pence in London.
For comments and feedback contact: editorial@rttnews.com
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.